Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ergoferon for Acute Upper Respiratory Tract Infections in Children
NCT01843842Phase 3Completed
- Sponsor
- Materia Medica Holding
- Start
- Apr 2013
- Primary completion
- Mar 2015
- Modality
- Antibody Conjugates, Monoclonal Antibodies, Engineered Antibody Formats
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in acute upper respiratory tract infection (URI) comparing Ergoferon with Placebo (2 arms). Primary endpoint: Percentage of Patients With Recovery/Improvement in Health at Day 4. Started Apr 2013; status: completed.
02
Drugs
Ergoferon
03
Conditions
acute upper respiratory tract infection (URI)
Beyond the preview
Go deeper on NCT01843842.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01843842.